TARS Tarsus Pharmaceuticals, Inc.
8-K Current Report
Filed: February 23, 2026
Health Care
Biological Products, (No Diagnostic Substances)Tarsus Pharmaceuticals, Inc. (TARS) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Full-year 2025 earnings results disclosed via press release (Exhibit 99.1)
- • Reporting period: fiscal year ended December 31, 2025
Get deeper insights on Tarsus Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.